KPV
Also known as: Lys-Pro-Val, Alpha-MSH(11-13)
A tripeptide representing the C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH). Retains the anti-inflammatory properties of α-MSH with superior stability.
Overview
KPV (Lysine-Proline-Valine) is the minimal bioactive fragment of α-MSH responsible for its potent anti-inflammatory activity. Full-length α-MSH (13 amino acids) exerts immunomodulatory effects through melanocortin receptors, but the tripeptide KPV was found to replicate these effects while being smaller and potentially more stable. It can penetrate cellular and intestinal barriers more efficiently than larger peptides.
Most research on KPV has focused on gut inflammation — particularly inflammatory bowel disease models where it shows strong protection of intestinal epithelium, reduction of inflammatory cytokines (IL-6, IL-8, TNF-α), and promotion of mucosal healing. Studies have also examined its topical applications for skin inflammation and wound healing.
Mechanism of Action
KPV primarily signals through melanocortin receptor 1 (MC1R) expressed on immune cells and epithelial cells. Receptor activation downregulates NF-κB and MAPK signaling, reducing pro-inflammatory cytokine production. It also upregulates anti-inflammatory mediators and promotes epithelial barrier repair.
Research Areas
- ●Inflammatory bowel disease (IBD) models
- ●Intestinal permeability and gut barrier research
- ●Skin inflammation and wound healing
- ●Oral delivery peptide pharmacology
- ●Colitis and Crohn's disease models
- ●Melanocortin receptor biology
Storage & Handling
Lyophilized: -20°C. Reconstituted: 2–8°C, 14 days.
Soluble in sterile water; highly stable compared to larger peptides
For Research Use Only. This information is provided for educational and research purposes. KPV is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.